Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat sodium for traumatic brain injury with ARDS
ChiCTR2400092469Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in traumatic brain injury (TBI) and acute respiratory distress syndrome (ARDS) comparing Sivelestat sodium with Placebo (2 arms). Primary endpoint: Improvement rate of the oxygenation index. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
traumatic brain injury (TBI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2400092469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092469.